May 17, 2020

The Christie NHS Foundation Joins Consortium to Develop Advanced Cancer Treatment

MR Linac Consortium
The Christie NHS Foundation
3 min
Early in April, the University Medical Center Utrecht began installing the first generation MRI-guided radiation therapy system for non-clinical testing.
MRI-guided radiation therapy has been a topic of discussion within the healthcare industry for well over a decade. The possibility of enhancing real-tim...

MRI-guided radiation therapy has been a topic of discussion within the healthcare industry for well over a decade. The possibility of enhancing real-time visualization of cancerous tissue during the delivery of radiation is a feat most doctors only dream of. That dream is seeing the light of reality, however, with the MR Linac Consortium.  

Headed by Elekta and supported by Royal Philips, the consortium aims to develop the clinical value of an integrated magnetic resonance imaging (MRI) guided radiation therapy system. Integration of technology between Elekta and Philips could allow doctors to adapt radiation therapy during the procedure, ultimately increasing treatment accuracy and reducing side effects.

On July 22, it was announced that The Christie NHS Foundation Trust in Manchester, UK, joined the consortium. The specialist cancer center is the seventh member to join.

“The Christie was an essential participant in the project 14 years ago that laid the foundations of the use of cone beam computed tomography [CBCT] at the time of treatment to improve radiotherapy delivery,” said Niklas Savander, Elekta president and CEO. “It has a dedicated team of researchers in medical physics, radiotherapy and clinical oncology and MR imaging that is committed to the most accurate and individualized delivery of radiation therapy. The Christie has the perfect blend of experience and expertise to further help the consortium make MRI-guided radiation therapy a reality.”

Radiotherapy is one of the primary modalities used to treat cancer, either as a stand-alone or paired with other modalities such as chemotherapy. The consortium’s new technique is a significant milestone towards the development of a clinical system capable of capturing highly detailed MR images of tumors and surrounding normal tissue as a patient receives radiotherapy.  

“We are very excited to be a part of an international consortium of truly exceptional centers that are striving as we are to develop technological innovations to benefit patients,” said Dr. Ananya Choudhury, Consultant and Honorary Senior Clinical Lecturer, Clinical Oncology at The Christie. “Unlike any imaging modality now in use in combination with radiotherapy, MRI can provide highly detailed images of the tumor and surrounding normal tissues. Moreover, MRI will permit physicians to non-invasively visualize and track the target during beam delivery – real-time imaging – which will further improve treatment accuracy.”

Launched in 2012, the MR Linac Consortium has already achieved great success in reaching its goal. Early in April, the University Medical Center Utrecht began installing the first generation MRI-guided radiation therapy system for non-clinical testing. Several of the sites are now undertaking treatment planning evaluation using the Monte Carlo based MRI-corrected algorithms in a research version of Elekta’s Monaco® treatment planning system.

Additionally, a number of consortium centers have active research programs linked to the system and have submitted abstracts to the American Association of Physicists in Medicine’s annual meeting, where specific sessions will be covering the latest advances in MRI-guided radiotherapy.  

In addition to The Christie NHS Foundation Trust and the University Medical Center Utrecht, other consortium members include The University of Texas MD Anderson Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, the Netherlands), Sunnybrook Health Sciences Centre (Toronto, Ontario), The Froedtert & Medical College of Wisconsin Cancer Center (Milwaukee, Wisconsin) and The Institute of Cancer Research, working with its clinical partner The Royal Marsden NHS Foundation Trust (London, England).

“When we first started this journey with Elekta and the University Medical Center Utrecht more than a decade ago, we already had a clear vision, yet we could only dream of today’s MRI imaging performance,” said Gene Saragnese, CEO Imaging Systems at Philips Healthcare. “Since then we have come a long way and I am convinced that with the current state of the technology and the growing consortium of leaders in radiation therapy delivery, we have the prerequisites to make the integrated MRI-guided radiation therapy technology a game changer in cancer care.”

The MRI-guided radiation therapy system is a work in progress and not available for sale or distribution.


Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article